City Center Advisors LLC Raises Stock Holdings in Kenvue Inc. (NYSE:KVUE)

City Center Advisors LLC increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 27.7% in the fourth quarter, HoldingsChannel reports. The firm owned 12,000 shares of the company’s stock after buying an additional 2,600 shares during the quarter. City Center Advisors LLC’s holdings in Kenvue were worth $256,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Leo Wealth LLC grew its holdings in shares of Kenvue by 0.3% during the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after buying an additional 481 shares in the last quarter. Alerus Financial NA grew its stake in Kenvue by 0.3% in the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after acquiring an additional 491 shares during the period. Massmutual Trust Co. FSB ADV raised its holdings in Kenvue by 6.2% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock valued at $194,000 after acquiring an additional 492 shares during the last quarter. Wolff Wiese Magana LLC lifted its stake in shares of Kenvue by 0.7% during the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after purchasing an additional 501 shares during the period. Finally, Marathon Capital Management boosted its holdings in shares of Kenvue by 0.3% during the second quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after purchasing an additional 514 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

NYSE:KVUE opened at $20.80 on Monday. The firm’s fifty day simple moving average is $22.62 and its 200 day simple moving average is $21.61. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The firm has a market capitalization of $39.88 billion, a price-to-earnings ratio of 37.82, a PEG ratio of 2.02 and a beta of 1.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.31 earnings per share. As a group, equities research analysts expect that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.94%. The ex-dividend date was Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and upped their target price for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Jefferies Financial Group began coverage on shares of Kenvue in a report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price objective on the stock. Bank of America raised their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Royal Bank of Canada raised shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and an average target price of $23.09.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.